بدائل البحث:
significant case » significant cause (توسيع البحث), significant based (توسيع البحث), significant change (توسيع البحث)
significant mean » significant main (توسيع البحث), significant gap (توسيع البحث), significant degs (توسيع البحث)
mean decrease » a decrease (توسيع البحث)
case based » made based (توسيع البحث), game based (توسيع البحث), rate based (توسيع البحث)
significant case » significant cause (توسيع البحث), significant based (توسيع البحث), significant change (توسيع البحث)
significant mean » significant main (توسيع البحث), significant gap (توسيع البحث), significant degs (توسيع البحث)
mean decrease » a decrease (توسيع البحث)
case based » made based (توسيع البحث), game based (توسيع البحث), rate based (توسيع البحث)
-
61
-
62
-
63
-
64
-
65
-
66
-
67
Deterministic result of the base-case analysis.
منشور في 2024"…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …"
-
68
-
69
Mean platelet volume and neutrophil to lymphocyte ratio decrease in patients with depression with antidepressant treatment
منشور في 2022"…When we look at admission and discharge scores of clinical scales, decrement is statistically significant for both HAM-D and CGI-S. There was decline both in MPV and NLR which were both statistically significant. …"
-
70
-
71
-
72
-
73
-
74
-
75
Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width.
منشور في 2021"…Shaded regions correspond to the standard error of the mean and dashed lines correspond to the peaks of each CAP, labeled with the same colors as the CAPs. …"
-
76
-
77
The base case analysis.
منشور في 2025"…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …"
-
78
-
79
Base-case results.
منشور في 2025"…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …"
-
80